

Author's response to reviews

Title: Efficacy and safety of the human anti-interleukin (IL)-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Authors:

Rieke Alten (rieke.alten@schlosspark-klinik.de)
Juan Gomez-Reino (juan.gomez-reino.carnota@sergas.es)
Patrick Durez (Patrick.durez@ruma.ucl.ac.be)
Andre Beaulieu (ab5@videotron.ca)
Anthony Sebba (asebba@tampabay.rr.com)
Gerhard Krammer (gerhard.krammer@novartis.com)
Ralph Preiss (ralph.preiss@novartis.com)
Udayasankar Arulmani (udayasankar.arulmani@novartis.com)
Albert Widmer (albert.widmer@novartis.com)
Xavier Gitton (xavier.gitton@novartis.com)
Herbert Kellner (hk@prof-dr-kellner.de)

Version: 5 Date: 27 June 2011

Author's response to reviews:

Dear Editor,

we have performed the required changes according to your proposal. We did not delete the vertical lines in the tables and would ask you kindly to do this for us.

We checked our manuscript for any typographical errors. So, we hope we can look forward to the publication soon.

Thank you very much for you patience.

Yours sincerely

Rieke Alten